On July 15, 2026, Shenzhen Cell Valley Biopharmaceutical Group Co., Ltd. successfully convened its 2026 Mid-Year Management Summary Meeting. The meeting was chaired by Chairman and General Manager Shi Yuanyuan, with Chief Scientist Wang Jianxun, Deputy General Manager and General Manager of subsidiary Shenzhen-Hong Kong Cell Valley Tang Xiaomeng, and heads of various business and functional departments in attendance.

        Centered on the theme of "review and reflect, build momentum, and secure year-end success," the meeting comprehensively reviewed the company's operational and construction achievements in the first half of the year across four key areas: market expansion and international business, qualification and compliance development, production and R&D systems, and internal management and logistics support. The meeting systematically outlined major tasks for the second half and rallied all staff toward achieving annual targets.

Deepening Domestic and International Markets, Achieving New Breakthroughs in International Medical Services

        The Cell Valley Group achieved coordinated momentum in both domestic and international markets during the first half. Domestically, the company focused on core pipelines including CAR-T, CAR-NK, NK, γδT cells, and exosomes, deepening clinical collaborations with multiple top-tier tertiary hospitals and continuously upgrading service capabilities. In terms of industrial layout, the company established four major bases in Guangzhou, Fujian-MinTai, Shenyang, and Qiaogang, covering key regions in Central China, South China, and Northeast China. Internationally, the group completed the standardization of cross-border service systems, deepened its presence in the German, Southeast Asian, and Middle Eastern markets, and launched cross-border referral and multilingual full-process medical services capable of serving overseas oncology patients on a regular basis. Collaborations with Brazilian medical institutions were established, and the company joined hands with China Meheco and Danaher Group to build a global R&D center, steadily enhancing its international brand influence.

Strengthening the Compliance Foundation, Standardizing Full-Chain Quality Control Systems

        In the first half, the group reinforced its core compliance and quality foundation, strictly benchmarking against industry standards including CNAS and GMP, and establishing a compliant quality management system covering the entire process of R&D, production, testing, and import/export. The company continuously optimized testing methods, revised quality standard documents, customized quality control standards for cell preparations, completed internal laboratory audits, certification renewals, and proficiency testing by the National Institutes for Food and Drug Control, and optimized and validated testing processes for multiple cell preparations. In terms of international qualification certification, the group obtained the international INCI filing for NK exosome cosmetics, FDA CBER international certification for the NK cell preparation system, and FDA DMF filing for gene delivery technologies – multiple industry-first compliance achievements that significantly enhanced the group's international compliance competitiveness.

Iterating Production and R&D Infrastructure, Accelerating Pipeline Technology Translation and Efficiency

        The group deepened its focus on technology R&D and production capacity development in the first half, opening up the full translation pathway from laboratory R&D to pilot manufacturing to large-scale production. CAR series, NK, and γδT cell self-development and CRO collaboration projects advanced on schedule. The company continuously optimized exosome and cell preparation testing processes while advancing new drug development and patent portfolios. The core technology for large-scale immune cell preparation was granted a national invention patent. In terms of production capacity, multiple cell preparations and exosome products achieved stable batch output, enhancing the quality and efficiency of the integrated vector, cell, and clinical industry chain. The efficiency of industrialization implementation and market delivery capacity were effectively improved.

Optimizing Internal Governance Systems, Enhancing Logistics Support Quality and Efficiency

        The group advanced comprehensive upgrades in internal governance, talent development, digital operations, and logistics support in the first half. Organizational structures were optimized to accommodate the nationwide multi-base layout and business needs, establishing a tiered performance uation system and a full-cycle talent development framework to strengthen talent pipelines. A digital management system was fully implemented, achieving a closed-loop online process for document management, quality testing, and client business, improving operational efficiency and cross-functional coordination. The logistics support system continued to improve quality and efficiency, providing regular support for the efficient operation of various business units and regional projects.

       In his concluding remarks, Chairman Shi Yuanyuan fully affirmed the achievements of all departments in the first half of 2026, particularly highlighting the company's breakthrough progress in frontier technology R&D, nationwide industrial layout, and global compliance filings. He stated that the company will continue to uphold its mission of "Cells benefit all, genes create the future," deepening its commitment to the clinical translation of cell and gene therapy, striving to build a one-stop technology service platform, and continuously advancing cell therapy toward standardized mass production, large-scale application, and international expansion.